Kalmbach Thomas Peter sold $4.6M of GL

Kalmbach Thomas Peter (EVP & CFO) sold 25,650 shares of GLOBE LIFE INC. (GL) at an average of $178.58 ($178.06–$179.42, $4.58M total) across 3 trades on 2026-07-28.

Original reporting
SEC EDGAR · Kalmbach Thomas Peter
Published Jul 29, 2026, 10:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 29, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GL
Neutral
medium confidence
Mentioned
$GL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLNeutralLow
01

Why it matters

The disclosure updates the market on insider selling activity and the CFO’s remaining direct holdings, but it does not provide new company fundamentals.

02

Market read

Traders may monitor GL for sentiment effects from insider selling, but there is no new operational or financial catalyst in the text.

03

What to watch

The absence of a stated 10b5-1 plan can increase attention, but the filing still lacks any stated reason for the sale or linkage to company performance.

Relevance 6/10Novelty 3/10Timing: filed after-hours on 2026-07-29 for trades dated 2026-07-28

Background

The article is an SEC Form 4 insider transaction report for Globe Life Inc. (GL).

Company-level read

Ticker impact

$GLNeutralMedium confidence
Context

Kalmbach Thomas Peter, GL’s EVP and CFO, sold 25,650 shares in open-market trades for about $4.58M on 2026-07-28.

Expected impact

Likely limited near-term impact; traders may view it as modestly bearish sentiment but not a fundamental catalyst.

Evidence & confidence

Form 4 provides transaction details (size, price range, post-sale holdings) but the filing does not disclose new guidance, contracts, or business developments.

Market effects

No clear sector read-through; this is an issuer-specific insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, so the signal may be weak.

Key entities

  • Globe Life Inc.

    Subject of the Form 4 insider sale by its EVP and CFO.

  • Kalmbach Thomas Peter

    EVP and CFO who sold 25,650 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BEMedAI 8/10

Why Stocks Like Bloom Energy and Globe Life Slumped

Bloom Energy (BE) fell 8% despite a 138.9% revenue increase and EPS beat, due to concerns over future revenue and capital expenditure. Globe Life (GL) dropped 8% after reporting 5.3% revenue growth and warning of FY 2026 headwinds. Comfort Systems (FIX) declined 9.26% despite strong earnings and revenue growth, citing higher material costs.

$GLMed

Globe Life Inc (GL) Q3 2026 Earnings Call Highlights: Premium Growth and Buybacks Offset

Globe Life Inc (GL) reported Q3 2026 earnings with total premium revenue up 7%, health premium revenue up 16%, and book value per share rising 23%. The company returned $210M to shareholders and expects to return near 70% of full-year net operating income. However, net income decreased 2%, life underwriting margin fell 5%, and full-year 2026 net operating EPS guidance was reduced to $15.35-$15.65. Management discussed various challenges and strategic plans during the earnings call.

$GLMed

Piper Sandler cuts Globe Life stock rating on medical claims concerns

Piper Sandler downgraded Globe Life (NYSE:GL) to Neutral, lowering its price target to $165 from $200 due to concerns over medical claims volatility. The stock trades at $168.41 with a P/E ratio of 10.97. Q3 results showed revenue of $1.6B, beating estimates, but EPS missed at $4.84. The firm cited exposure to medical claims severity and irregularity in Medicare supplement claims as key issues.